Mohs Micrographic Surgery Technique
Mohs micrographic surgery (MMS) is a specialized surgical technique that provides 360-degree peripheral and deep margin assessment, evaluating approximately 100% of the surgical margin. The Mohs surgeon serves as both surgeon and pathologist, performing staged excision with complete margin evaluation to achieve the highest cure rates while maximizing tissue conservation.
By Dr. Yehonatan Kaplan (M.D., Fellow ACMS)·Published: 2025-03-01·Updated: 2026-03-15·Reviewed: 2026-03-07
Mohs micrographic surgeryfrozen sectionmargin assessmenttissue processingBCCSCCcure ratetechnique
Fundamental Principles
Mohs micrographic surgery is based on two foundational principles. First, cutaneous tumors grow by contiguous extension. They spread as a continuous mass of connected tumor cells rather than by "skip" metastases through the skin. This principle means that if the entire peripheral and deep margin is clear of tumor, the remaining tissue is tumor-free. Second, the technique evaluates essentially 100% of the surgical margin by using horizontal (en face) frozen sections of the entire tissue edge. In contrast to standard bread-loaf histologic sectioning which evaluates only 1-2% of the true margin. This complete margin assessment explains the superior cure rates of Mohs surgery (99% for primary BCC, 94-95% for recurrent BCC) compared to standard excision.
Indications for Mohs Surgery
Mohs micrographic surgery is indicated when the clinical scenario demands either maximal cure rate or maximal tissue conservation (or both). The indications are guided by NCCN guidelines, AAD/ACMS appropriate use criteria, and clinical judgment.
Tumor-Related Indications
Mohs is indicated for tumors with features that increase the risk of incomplete excision or recurrence. These include recurrent tumors (previously treated but returned), incompletely excised tumors (positive margins on prior excision), aggressive histologic subtypes (infiltrative, morpheaform, micronodular BCC; desmoplastic, poorly differentiated SCC), perineural invasion (PNI) on biopsy, ill-defined clinical borders (boundaries not clearly visible), large tumor size (greater than 2 cm), and tumors arising in immunosuppressed patients.
Location-Based Indications
Mohs is indicated for tumors in high-risk locations where tissue conservation is critical and recurrence rates with standard excision are unacceptably high. These are defined by the NCCN anatomic zones.
| Zone | Areas | Rationale for Mohs |
|---|---|---|
| H-zone (high risk) | Central face: nose, periorbital, eyelids, lips, chin, ear, temple, periauricular; genitalia | Highest recurrence risk with standard excision; tissue conservation critical for functional and cosmetic outcomes; complex anatomy with potential for deep/perineural extension |
| M-zone (medium risk) | Cheeks, forehead, scalp, neck, jawline, pretibial, hands, feet | Moderate recurrence risk; Mohs indicated when other high-risk features present (recurrence, aggressive subtype, PNI, large size) |
| L-zone (low risk) | Trunk, extremities (excluding pretibial, hands, feet) | Lowest recurrence risk; Mohs generally reserved for recurrent, multiply recurrent, or incompletely excised tumors |
Patient-Related Indications
Patient factors that favor Mohs include immunosuppression (organ transplant recipients, chronic immunosuppressive therapy), genetic predispositions (basal cell nevus/Gorlin syndrome, xeroderma pigmentosum), prior radiation to the surgical site, young patient age (maximizing tissue conservation for lifetime of sun exposure), and patient preference for maximal cure rate.
The 18-Step Mohs Process
The Mohs micrographic surgery workflow is a systematic, sequential process that ensures complete margin evaluation. Each step is critical to the accuracy and success of the procedure.
Step 1: Clinical Assessment and Marking
The tumor is examined clinically. The visible tumor margin is marked on the skin with a surgical marker. The patient is positioned, and local anesthesia (typically 1% lidocaine with 1:100,000 or 1:200,000 epinephrine) is infiltrated around and beneath the tumor. Time is allowed for epinephrine vasoconstriction (10-15 minutes optimal).
Step 2: Debulk (Curettage)
The clinically apparent tumor mass is debulked using a dermal curette. Curettage provides both debulking (reducing tissue volume for processing) and tactile mapping (the surgeon can feel the difference between soft/friable tumor and firm/gritty normal dermis). The curetted area is typically larger than the visible tumor and provides the surgeon with a more accurate estimate of subclinical tumor extent.
Step 3: Score the Epidermis
The surgeon scores (superficially incises) the epidermis in a geometric pattern around the debulked tumor site, typically 1-3 mm beyond the curetted margin. Score marks serve as orientation landmarks. They are visible on both the wound bed and the excised tissue, allowing precise mapping of tumor location back to the patient.
Step 4: Beveled Excision at 30-45 Degrees
The Mohs layer is excised with the scalpel blade angled at 30-45 degrees, beveling inward toward the wound base. This bevel angle is critical. It allows the tissue to be flattened (inverted) in the lab so that the entire peripheral margin and the deep margin lie in the same horizontal plane. Without the bevel, it would be impossible to see both the peripheral and deep margins on a single frozen section. The layer is typically 1-3 mm thick.
Step 5: Orientation on the Mohs Map
Before removing the tissue from the patient, orientation marks (hash marks, nicks, or ink colors) are placed at specific landmarks on the tissue edge. These marks correspond to a paper map (the Mohs map) that represents the surgical wound. The map preserves the spatial relationship between the tissue specimen and the patient. This is the key to knowing exactly WHERE to re-excise if tumor is found.
Step 6: Bisect (if needed)
If the tissue specimen is too large to fit on a single cryostat chuck, it is bisected (or trisected) into smaller pieces. Each piece receives orientation marks, and the map is updated to reflect the division. The bisection line must be straight and clean.
Step 7: Flatten (Press) the Tissue
The excised tissue is placed on a flat surface with the epidermal side down. The beveled peripheral edge is pressed flat so that it lies in the same plane as the deep surface. This step. Enabled by the 30-45 degree excision bevel. Is what allows the entire margin (peripheral + deep) to appear on a single horizontal section.
Step 8: Invert onto Cryostat Chuck
The flattened tissue is inverted (flipped) and mounted onto a cryostat chuck with the cut (deep) surface facing up. The tissue is oriented so that the peripheral and deep margins are uppermost. The microtome will section through these margins first.
Step 9: Mount with Embedding Medium
Optimal cutting temperature (OCT) compound is applied to embed the tissue on the chuck. The OCT provides a supporting matrix for frozen sectioning. The tissue must be flat and free of wrinkles or folds. Any artifact will cause gaps in margin evaluation.
Step 10: Freeze
The mounted specimen is frozen rapidly in the cryostat (typically at -20 to -30 degrees Celsius). Rapid freezing preserves cellular morphology and prevents ice crystal artifact.
Step 11: Microtome Sectioning
The frozen tissue is cut into thin sections (4-8 micrometers) using the cryostat microtome. The first few sections contain the surgical margin. These are the critical sections for margin evaluation. The histotechnician ensures that the ENTIRE margin is present in the section (no gaps, no areas of missing tissue). If any portion of the margin is not represented, deeper sections are cut until complete.
Step 12: Stain
The frozen sections are stained, most commonly with hematoxylin and eosin (H&E) or toluidine blue. H&E provides standard histologic morphology. Some laboratories use additional stains (immunohistochemistry such as cytokeratin, MART-1/Melan-A for melanoma) for specific tumor types.
Step 13: Read the Slides
The Mohs surgeon examines the stained sections under the microscope, evaluating the entire peripheral and deep margin for residual tumor. This is the pathologic component of the dual surgeon-pathologist role. The surgeon identifies tumor cells, assesses their histologic pattern, and determines their precise location relative to the margin.
Step 14: Map the Results
If tumor is identified on the frozen section, its location is marked on the Mohs map with precision. The orientation marks placed during excision allow the surgeon to translate the microscopic location of residual tumor back to the corresponding anatomical position on the patient. The map serves as the guide for the next excision layer.
Step 15: Re-excise if Positive
If the margin is positive (tumor present), the surgeon returns to the patient and excises an additional layer ONLY from the area where tumor was identified on the map. This targeted re-excision. Removing tissue only where tumor remains. Is what maximizes tissue conservation. The additional layer is processed through steps 5-14 again.
Step 16: Repeat Until Clear
Steps 3-15 are repeated as many times as necessary until the entire margin is clear of tumor on all sections. Each repetition is called a "stage" or "layer." The average number of stages is 1.5-2.0 for primary BCC.
Step 17: Clear Margin Achieved
Once all margins are clear, the surgeon has confirmed complete tumor removal. The remaining wound bed is tumor-free (assuming contiguous tumor growth).
Step 18: Reconstruction
The surgical defect is reconstructed using the optimal method: primary (linear) closure, local flap, skin graft, or secondary intention healing. Reconstruction is performed immediately after Mohs clearance in most cases.
The Threshold Layer Concept
The threshold layer concept, described by Phillips et al. (2022), addresses the question: how reliable is a "clear" Mohs margin? In their study, when a Mohs layer showed only a single small focus of residual tumor (threshold-positive), an additional layer was taken and found to be clear (threshold-negative) in 97.4% of cases. This finding suggests that the single focus of tumor in the threshold layer represented the very last tumor cells at the advancing front. The "threshold" between tumor and tumor-free tissue. The clinical implication is profound: a clear Mohs margin is extremely reliable. When the margin is clear, there is a greater than 97% probability that no residual tumor remains beyond that margin.
AUC (Appropriate Use Criteria) Areas
The American Academy of Dermatology (AAD) and American College of Mohs Surgery (ACMS) have published Appropriate Use Criteria (AUC) that define clinical scenarios where Mohs surgery is considered appropriate, uncertain, or inappropriate. The anatomical zones used in AUC mirror the NCCN zone system.
| AUC Zone | Anatomical Areas | Mohs Appropriateness |
|---|---|---|
| H (Area H) | Central face (nose, periorbital, eyelids, lips, chin), ears, temples, periauricular, genitalia, hands, feet, pretibial, nail unit | Mohs APPROPRIATE for nearly all BCC and SCC in this zone regardless of size or subtype |
| M (Area M) | Cheeks, forehead, scalp, neck, jawline | Mohs APPROPRIATE when high-risk features present (recurrent, aggressive subtype, PNI, large size, immunosuppressed) |
| L (Area L) | Trunk, extremities (excluding hands/feet/pretibial) | Mohs APPROPRIATE only for recurrent, incompletely excised, or tumors with multiple high-risk features |
Tissue Processing and Histology Pearls
The quality of Mohs histologic sections directly determines the accuracy of margin assessment. Poorly prepared slides can lead to false-negative results (missing residual tumor) or false-positive results (artifact mimicking tumor).
Common Histologic Artifacts and Pitfalls
Several artifacts can compromise Mohs slide quality. Freeze artifact (ice crystal formation) distorts cellular morphology and can mimic tumor. Rapid freezing minimizes this. Crush artifact from forceps handling can distort tissue architecture. Thick sections (greater than 8 micrometers) cause cell overlap and make interpretation difficult. Incomplete sections (the entire margin is not represented on the slide) leave gaps where tumor could be missed. This is the most dangerous artifact because it creates a false sense of margin clearance.
Staining Methods
Hematoxylin and eosin (H&E) is the standard stain for Mohs surgery. Toluidine blue is an alternative that highlights BCC cells with excellent contrast and faster staining time. For melanoma, immunohistochemistry with MART-1/Melan-A or SOX-10 is increasingly used in conjunction with H&E to identify melanocytes at the margin that may not be visible on standard staining. For SCC with perineural invasion, S-100 and cytokeratin immunostains help identify nerve involvement.
Mohs vs. Standard Excision
Understanding the differences between Mohs and standard excision is essential for appropriate surgical planning and patient counseling.
| Parameter | Mohs Micrographic Surgery | Standard Surgical Excision |
|---|---|---|
| Margin assessment | ~100% of margin evaluated (horizontal en face sections) | ~1-2% of margin evaluated (vertical bread-loaf sections) |
| Intraoperative control | Yes. Margin assessed before reconstruction | No. Margin result available days-weeks later on permanent sections |
| Cure rate (primary BCC) | 99% | 95-96% (with adequate margins) |
| Cure rate (recurrent BCC) | 94-95% | 82-90% |
| Tissue conservation | Maximum. Only tumor-positive tissue removed | Predetermined margins (4mm BCC, 4-6mm SCC). More tissue removed |
| Surgeon role | Surgeon AND pathologist (same physician) | Surgeon excises; separate pathologist reads slides |
| Time | Longer operative day (staged, with lab processing between stages) | Single procedure, shorter operative time |
| Cost | Higher initial cost (offset by single-stage completion and lower recurrence) | Lower initial cost (but higher if re-excision needed for positive margins) |
Limitations and Contraindications
Mohs micrographic surgery, despite its advantages, has specific limitations. The technique relies on the assumption of contiguous tumor growth. Tumors that metastasize discontinuously through the skin (rare) may not be fully cleared by Mohs. Certain tumor types are difficult to interpret on frozen sections, including dermatofibrosarcoma protuberans (DFSP), melanoma (requires immunohistochemistry), and spindle cell tumors. For melanoma, many centers use a "slow Mohs" or staged excision with rush permanent sections and immunohistochemistry rather than traditional frozen section Mohs. Patient factors such as inability to tolerate a prolonged procedure, anticoagulation with very high bleeding risk, or extremely large tumors requiring multidisciplinary oncologic management may favor other approaches.
Frequently Asked Questions
Related Articles
Mohs Lab: Tissue Processing & Frozen Section HistologySurgical Danger ZonesUndermining Planes by Anatomical RegionSurgical Instruments in Dermatologic SurgerySuturing TechniquesFull-Thickness Skin Grafts (FTSG)Composite Grafts, Split-Thickness Grafts, and Free Cartilage GraftsCPT Coding & Billing for Mohs Surgery
Recent Evidence
From the Northwestern Medicine Dermatologic Surgery Journal Club
Fraga SD, Besaw RJ, Murad F, et al. · Dermatol Surg (2022)
Soleymani T, Brodland DG, Arzeno J, et al. · J Am Acad Dermatol (2022)
Kesty K, Sangueza OP, Leshin B, et al. · J Am Acad Dermatol (2017)
Patel P, Guzman AK, Tinklepaugh A, et al. · J Drugs Dermatol (2021)
References
- [1]Chen ELA, Srivastava D, Nijhawan RI. Mohs Micrographic Surgery: Development, Technique, and Applications in Cutaneous Malignancies. Semin Plast Surg. 2018. doi:10.1055/s-0038-1642057 PMID: 29765269
- [2]Robinson JK, Hanke CW, Siegel DM, Fratila A. Surgery of the Skin: Procedural Dermatology, 3rd Edition. Elsevier. 2019.
- [3]National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer v1.2026. NCCN Guidelines. 2026.
- [4]National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer v1.2026. NCCN Guidelines. 2026.
- [5]Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol. 2005. doi:10.1016/j.jaad.2004.09.052 PMID: 15793512
- [6]Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery. J Am Acad Dermatol. 2012. doi:10.1016/j.jaad.2012.06.009 PMID: 22959232
About This Article
Author: Dr. Yehonatan Kaplan, M.D., Fellow ACMS
Last Medical Review:
Audience: Dermatologic Surgeons
Clinic: Kaplan Clinic · DermUnbound Research Program